{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+matching+moxifloxacin+tablet", "query": { "intervention": "Placebo matching moxifloxacin tablet" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 53, "total_pages": 6, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+matching+moxifloxacin+tablet&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-02T10:18:25.562Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02479308", "title": "A Study to Evaluate the Effect of ALKS 5461 on QT Intervals in Healthy Volunteers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Moxifloxacin", "type": "DRUG" }, { "name": "ALKS 5461", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alkermes, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 129, "start_date": "2015-06", "completion_date": "2015-10", "has_results": false, "last_update_posted_date": "2015-11-23", "last_synced_at": "2026-10-02T10:18:25.562Z", "location_count": 1, "location_summary": "Overland Park, Kansas", "locations": [ { "city": "Overland Park", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02479308" }, { "nct_id": "NCT02222324", "title": "A Study to Evaluate the Effects of E2609 on QTc Interval in Healthy Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Subjects" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "E2609", "type": "DRUG" }, { "name": "Moxifloxacin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eisai Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 60, "start_date": "2014-08", "completion_date": "2014-12", "has_results": false, "last_update_posted_date": "2015-11-03", "last_synced_at": "2026-10-02T10:18:25.562Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02222324" }, { "nct_id": "NCT03155893", "title": "A Study to Evaluate the Cardiac Safety of a Single Dose of AL-335 Administered on a Background of Simeprevir and Odalasvir and of Repeated Doses of Odalasvir Administered Alone in Healthy Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "ODV Placebo (Matching 25 mg ODV)", "type": "DRUG" }, { "name": "ODV Placebo (Matching 200 mg ODV)", "type": "DRUG" }, { "name": "ODV Placebo (Matching 125 mg ODV)", "type": "DRUG" }, { "name": "ODV Placebo (Matching 100 mg ODV)", "type": "DRUG" }, { "name": "SMV Placebo (Matching 150 mg SMV)", "type": "DRUG" }, { "name": "AL-335 Placebo (matching 1200 mg AL-335)", "type": "DRUG" }, { "name": "Moxifloxacin Placebo (matching 400 mg moxifloxacin)", "type": "DRUG" }, { "name": "ODV 25 mg", "type": "DRUG" }, { "name": "ODV 200 mg", "type": "DRUG" }, { "name": "ODV 125 mg", "type": "DRUG" }, { "name": "ODV 100 mg", "type": "DRUG" }, { "name": "SMV 150 mg", "type": "DRUG" }, { "name": "AL-335 1200 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 59, "start_date": "2017-05-12", "completion_date": "2017-10-27", "has_results": false, "last_update_posted_date": "2017-11-14", "last_synced_at": "2026-10-02T10:18:25.562Z", "location_count": 1, "location_summary": "Tempe, Arizona", "locations": [ { "city": "Tempe", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT03155893" }, { "nct_id": "NCT05293171", "title": "Study to Investigate the Effect of BL-8040 (Motixafortide) on the QTc Interval in Healthy Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Subjects" ], "interventions": [ { "name": "1.25 mg/kg BL-8040 + BL-8040-matching placebo", "type": "DRUG" }, { "name": "2 mg/kg BL-8040", "type": "DRUG" }, { "name": "BL-8040-matching placebo", "type": "DRUG" }, { "name": "400 mg Moxifloxacin (1x400 mg tablet)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BioLineRx, Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 38, "start_date": "2021-06-11", "completion_date": "2022-08-15", "has_results": true, "last_update_posted_date": "2025-03-21", "last_synced_at": "2026-10-02T10:18:25.562Z", "location_count": 1, "location_summary": "Phoenix, Arizona", "locations": [ { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT05293171" }, { "nct_id": "NCT01999114", "title": "The Effect of Buprenorphine Delivered by Buprenorphine Transdermal System (BTDS) at Doses up to 80 Micrograms/Hour (mcg/hr) and Naltrexone on Electrocardiogram (ECG) Intervals in Healthy Volunteers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "ECG Effects" ], "interventions": [ { "name": "Buprenorphine transdermal patch", "type": "DRUG" }, { "name": "Naltrexone tablet", "type": "DRUG" }, { "name": "Placebos (for TDS and for naltrexone and for moxifloxacin)", "type": "DRUG" }, { "name": "Moxifloxacin tablet", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Purdue Pharma LP", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 328, "start_date": "2012-03", "completion_date": "2012-10", "has_results": true, "last_update_posted_date": "2018-11-05", "last_synced_at": "2026-10-02T10:18:25.562Z", "location_count": 1, "location_summary": "Austin, Texas", "locations": [ { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01999114" }, { "nct_id": "NCT05016206", "title": "A Study of the Cardiac Effects of Danicopan in Healthy Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Danicopan", "type": "DRUG" }, { "name": "Moxifloxacin-matching Placebo", "type": "DRUG" }, { "name": "Danicopan-matching placebo", "type": "DRUG" }, { "name": "Moxifloxacin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alexion Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 33, "start_date": "2018-07-26", "completion_date": "2018-10-12", "has_results": false, "last_update_posted_date": "2021-08-23", "last_synced_at": "2026-10-02T10:18:25.562Z", "location_count": 1, "location_summary": "Tempe, Arizona", "locations": [ { "city": "Tempe", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT05016206" }, { "nct_id": "NCT03958123", "title": "Evaluation of the Effects of Multiple Doses of Cebranopadol on the Electrical Activity of the Heart in Healthy Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Prolonged QTc Interval", "Pharmacokinetic" ], "interventions": [ { "name": "100 μg cebranopadol", "type": "DRUG" }, { "name": "200 μg cebranopadol", "type": "DRUG" }, { "name": "400 μg cebranopadol", "type": "DRUG" }, { "name": "Placebo to cebranopadol encapsulated tablets", "type": "DRUG" }, { "name": "400 mg Moxifloxacin", "type": "DRUG" }, { "name": "Placebo to moxifloxacin encapsulated tablets", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tris Pharma, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 171, "start_date": "2013-07-10", "completion_date": "2013-11-27", "has_results": false, "last_update_posted_date": "2021-07-15", "last_synced_at": "2026-10-02T10:18:25.562Z", "location_count": 1, "location_summary": "West Bend, Wisconsin", "locations": [ { "city": "West Bend", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT03958123" }, { "nct_id": "NCT02293148", "title": "Single Dose, Pharmacokinetic, Safety, Tolerability and QTc Study of GSK1278863 in Healthy Volunteers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Anaemia" ], "interventions": [ { "name": "GSK1278863 75 mg", "type": "DRUG" }, { "name": "GSK1278863 500 mg", "type": "DRUG" }, { "name": "Moxifloxacin 400 mg", "type": "DRUG" }, { "name": "Placebo matching GSK1278863", "type": "DRUG" }, { "name": "Placebo matching Moxifloxacin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 61, "start_date": "2014-11-17", "completion_date": "2015-03-10", "has_results": false, "last_update_posted_date": "2018-07-24", "last_synced_at": "2026-10-02T10:18:25.562Z", "location_count": 1, "location_summary": "Overland Park, Kansas", "locations": [ { "city": "Overland Park", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02293148" }, { "nct_id": "NCT02785770", "title": "A Study To Evaluate The Effect Of PF-04447943 On Qtc Interval In Healthy Adult Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "PF-04447943", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Moxifloxacin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 44, "start_date": "2016-06-29", "completion_date": "2016-10-20", "has_results": true, "last_update_posted_date": "2018-12-28", "last_synced_at": "2026-10-02T10:18:25.562Z", "location_count": 1, "location_summary": "New Haven, Connecticut", "locations": [ { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT02785770" }, { "nct_id": "NCT02217930", "title": "Study to Evaluate the Effect Of WCK 2349 on the QT/QTc Interval in Health Volunteers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Qt Interval, Variation in" ], "interventions": [ { "name": "WCK 2349", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Moxifloxacin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Wockhardt", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 80, "start_date": "2014-08", "completion_date": "2015-07", "has_results": false, "last_update_posted_date": "2015-10-29", "last_synced_at": "2026-10-02T10:18:25.562Z", "location_count": 1, "location_summary": "West Bend, Wisconsin", "locations": [ { "city": "West Bend", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT02217930" } ] }